PEPTIDES
A Hot Topic in Anti-Ageing and Wellness
BPC 157 5
BP BPC 157 5 mg, is a peptide with a growing reputation for its potential therapeutic benefits and limited side effects. Below, we explore the advantages, potential side effects, detailed dosage instructions, and half-life associated with BPC157.
Benefits of BPC157 (5mg):
Tissue Healing: BPC157 may accelerate the healing of various tissues, including muscles, tendons, ligaments, and your organs. It promotes tissue regeneration and repair, which may help individuals recover from injuries more swiftly.
Reduced Inflammation: BPC157 exhibits anti-inflammatory properties, potentially mitigating the inflammation associated with injuries or certain medical conditions.
Pain Management: Users have reported a reduction in pain and discomfort, particularly in cases of musculoskeletal injuries and joint issues.
Gastrointestinal Health: BPC157 may contribute to the maintenance of gastrointestinal health by aiding in the repair of the gut lining and potentially alleviating digestive issues.
Dosage Instructions:
Dosage instructions for BPC 157 (5mg) can vary based on individual needs and the advice of a healthcare provider. BPC157 is typically administered via subcutaneous or intramuscular injections. Here are general guidelines:
Dosage: Common dosages range from 250 to 500 micrograms (µg) per day, divided into multiple injections.
Injection Frequency: Typically, a user administers BPC 157 5 mg injections once or twice a day.
Duration of Use: The duration of use may vary, but healthcare providers often recommend using BPC 157 for several weeks to months, followed by periods of rest.
It is crucial to consult with a qualified healthcare provider before starting a BPC157 regimen to determine the appropriate dosage and duration of use based on individual health needs.
Side Effects:
BPC 157 5 mg is generally considered safe and well-tolerated. However, like any substance, it may have potential side effects, which are typically mild and infrequent. These may include:
Injection Site Reactions: Users may experience minor irritation, redness, or swelling at the injection site.
Gastrointestinal Issues: Some individuals have reported mild digestive discomfort, but this is relatively rare.
Allergic Reactions: Although rare, allergic reactions are possible, so users should monitor for signs such as hives or difficulty breathing.
It’s essential to remember that side effects can vary among individuals, and severe adverse effects are uncommon.
Half-Life:
BPC157 has a relatively short half-life, estimated to be approximately 2-3 hours. This means that the body rapidly metabolizes and clears it. As a result, healthcare providers typically recommend multiple daily injections to maintain consistent levels of BPC157 in the bloodstream.
In summary, BPC157 (5mg) is a peptide with potential therapeutic benefits, particularly in tissue healing, inflammation reduction, pain management, and gastrointestinal health. Limited side effects can occur, but it is generally considered safe. Proper dosage instructions and guidance from a healthcare provider are crucial for those considering BPC157 as part of their treatment regimen.
Peptides
Customised For Your Needs
PEPTIDES
Hot Items in Anti-ageing and Wellness
Melanotan II 10
BP Melanotan II 10mg, is a synthetic peptide known for its potential benefits in promoting skin tanning and, to some extent, enhancing sexual arousal.
Below, we explore the advantages, potential side effects, detailed dosage instructions, and half-life associated with Melanotan II.
Benefits of Melanotan II (10mg):
Skin Tanning: It is primarily used to stimulate the production of melanin, the pigment responsible for skin colour. This results in a deepening of skin pigmentation, often referred to as a “tan.” The potential benefits include:
Sunless Tanning: Melanotan II offers a sunless tanning alternative, reducing the need for prolonged sun exposure, which can be harmful to the skin.
UV Protection: The increased melanin production may provide some degree of protection against the harmful effects of ultraviolet (UV) radiation from the sun.
Libido Enhancement: Some users have reported increased sexual arousal and desire as a secondary effect of Melanotan II use.
Dosage Instructions:
Dosage instructions for Melanotan II (10mg) can vary based on individual goals and personal response. Typically, people administer it through subcutaneous injections. Here are general guidelines:
Loading Phase: Many users start with a “loading phase” to quickly achieve the desired tan. During this phase, they may inject 0.5 to 1mg daily until the desired skin pigmentation is reached.
Maintenance Phase: After achieving the desired tan, users may switch to a “maintenance phase”. A user can inject 0.5 to 1mg every 2-3 days to maintain the tan.
Libido Enhancement: For libido enhancement, some users may take lower doses (typically 0.1 to 0.5mg). 1-2 hours before anticipated sexual activity.
It is essential to consult with a qualified healthcare provider for precise dosage instructions tailored to individual health needs and goals.
Side Effects:
Melanotan II may have potential side effects, although these can vary among individuals. Some common side effects may include:
Nausea: Some users experience mild nausea, particularly during the loading phase.
Facial Flushing: Flushing or redness of the face and skin can occur, especially during the initial injections.
Appetite Suppression: Melanotan II may temporarily suppress appetite in some individuals.
Darkening of Moles: Existing moles may darken with Melanotan II use, and new moles may appear.
Priapism: In rare cases, men may experience priapism, a prolonged and painful erection. This is a severe side effect that requires immediate medical attention.
Half-Life:
Melanotan II has a relatively short half-life, estimated to be approximately 30 minutes to 2 hours. This means that the body rapidly clears it after administration. Consequently, some users may need to administer multiple daily injections during the loading phase to achieve and maintain the desired tan.
It is essential to use this peptide responsibly and under medical supervision, as individual responses and side effects can vary. Precise dosage instructions and consultation with a healthcare provider are crucial for individuals considering Melanotan II as part of their regimen. Users should be aware that Melanotan II carries potential risks, especially in cases of priapism or excessive UV exposure.
Peptides
Customised For Your Needs
Peptide Price List (SR)
Somatropin 100iu kit
10x10iu+10ml
SR2,040.0
HCG 5000iu
5000iu/3ml+2ml
SR300.0
Gonadorelin 2mg
2mg/3ml+2ml
SR264.0
Melanotan MT2 10mg
10mg/3ml+2ml
SR264.0
GHRP-6 5mg
5mg/3ml+2ml
SR264.0
BPC-157 5mg
5mg/3ml+2ml
SR264.0
CJC 1295 DAC 2mg
2mg/3ml+2ml
SR324.0
IGF 1 LR3 0.1mg
0.1mg/3ml+2ml
SR264.0
Ipamorelin 5mg
5mg/3ml+2ml
SR288.0
Tesamorelin 5mg
5mg/3ml+2ml
SR264.0
TB500 5mg
5mg/3ml+2ml
SR324.0
AOD9604 2mg
2mg/3ml+2ml
SR264.0
New: "Retatrutide"
Retatrutide
Eli Lilly’s retatrutide is a next-generation investigational drug that targets obesity, demonstrating remarkable weight loss and metabolic benefits in clinical studies. It is a “triagonist,” activating three key receptors: GLP-1, GIP, and glucagon. This unique combination allows it to improve glucose control, enhance insulin sensitivity, and increase energy expenditure, distinguishing it from other drugs in its class, like semaglutide (Wegovy) and tirzepatide (Mounjaro).
In a Phase 2 study involving 338 participants with obesity or weight-related conditions, retatrutide showed impressive results. Patients on the highest dose (12 mg) experienced a 24.2% reduction in body weight over 48 weeks, averaging 58 pounds of weight loss. Notably, the study ended before participants reached a weight plateau, indicating the potential for even greater efficacy in longer trials. The drug also improved cardiometabolic measures, including cholesterol, blood pressure, and blood sugar levels, making it a promising option for comprehensive metabolic management.
The safety profile of retatrutide is consistent with other incretin-based therapies, with gastrointestinal side effects being the most common and dose-dependent. To mitigate side effects, the trial employed a gradual dose escalation strategy. The Phase 3 TRIUMPH program is currently underway, aiming to further evaluate retatrutide’s efficacy and tolerability for long-term weight management, as well as its impact on related conditions such as sleep apnea and knee osteoarthritis.
Overall, retatrutide represents a significant advancement in obesity treatment and is positioned to play a key role in Eli Lilly’s expanding pipeline of metabolic therapies.
The U.S. Food and Drug Administration (FDA) oversees a series of clinical trial phases to evaluate new drugs for safety, efficacy, and overall benefit-risk profile before approval for public use. Here are the phases:
1. Preclinical Studies
• Goal: Assess initial safety and biological activity in non-human models.
• Process: Conducted in laboratory and animal studies to determine toxicity, dosage, and pharmacokinetics (how the drug moves through the body).
• Outcome: If promising, the drug sponsor submits an Investigational New Drug (IND) application to the FDA to begin human trials.
2. Phase 1: First-in-Human Trials
• Goal: Evaluate safety, dosage range, and pharmacokinetics in humans.
• Participants: 20–100 healthy volunteers or people with the disease/condition (depending on the drug’s nature).
• Key Activities: Escalating doses to find the maximum tolerable dose and understand side effects.
• Outcome: Identify a safe dosage range and observe drug behaviour in the human body.
3. Phase 2: Proof-of-Concept Trials
• Goal: Assess drug efficacy and side effects in a targeted patient population.
• Participants: 100–300 individuals with the disease/condition.
• Process: Typically randomized and controlled, comparing the drug to a placebo or standard treatment.
• Outcome: Gather preliminary data on efficacy and confirm safety findings from Phase 1.
4. Phase 3: Pivotal Trials
• Goal: Confirm effectiveness, monitor side effects, and compare the drug to current standard treatments.
• Participants: 300–3,000+ patients across multiple sites.
• Design: Double-blind, randomized controlled trials to minimise bias.
• Outcome: Comprehensive data for submission in a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA for approval.
5. FDA Review and Approval
• Review: After submission of the NDA or BLA, the FDA evaluates all trial data to decide on approval.
• Advisory Committees: External experts may provide recommendations, though the FDA makes the final decision.
6. Phase 4: Post-Marketing Surveillance
• Goal: Monitor long-term safety and effectiveness after FDA approval.
• Participants: Broad population using the drug in real-world settings.
• Activities: Detect rare side effects, ensure ongoing efficacy, and evaluate additional uses.
• Outcome: This may lead to label changes, additional warnings, or even withdrawal of the drug.
This phased approach ensures new drugs are rigorously evaluated for both safety and efficacy before reaching the market.